These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 24713186)

  • 1. Patient-reported outcomes assessment in chronic hepatitis C treated with sofosbuvir and ribavirin: the VALENCE study.
    Younossi ZM; Stepanova M; Zeuzem S; Dusheiko G; Esteban R; Hezode C; Reesink HW; Weiland O; Nader F; Hunt SL
    J Hepatol; 2014 Aug; 61(2):228-34. PubMed ID: 24713186
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient-reported outcomes in chronic hepatitis C patients with cirrhosis treated with sofosbuvir-containing regimens.
    Younossi ZM; Stepanova M; Nader F; Jacobson IM; Gane E; Nelson D; Lawitz E; Hunt SL
    Hepatology; 2014 Jun; 59(6):2161-9. PubMed ID: 24710669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of ledipasvir/sofosbuvir on patient-reported outcomes in cirrhotic patients with chronic hepatitis C: the SIRIUS study.
    Younossi ZM; Stepanova M; Pol S; Bronowicki JP; Carrieri MP; Bourlière M
    Liver Int; 2016 Jan; 36(1):42-8. PubMed ID: 26059860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient-reported outcomes with sofosbuvir and velpatasvir with or without ribavirin for hepatitis C virus-related decompensated cirrhosis: an exploratory analysis from the randomised, open-label ASTRAL-4 phase 3 trial.
    Younossi ZM; Stepanova M; Charlton M; Curry MP; O'Leary JG; Brown RS; Hunt S
    Lancet Gastroenterol Hepatol; 2016 Oct; 1(2):122-132. PubMed ID: 28404069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Minimal impact of sofosbuvir and ribavirin on health related quality of life in chronic hepatitis C (CH-C).
    Younossi ZM; Stepanova M; Henry L; Gane E; Jacobson IM; Lawitz E; Nelson D; Nader F; Hunt S
    J Hepatol; 2014 Apr; 60(4):741-7. PubMed ID: 24333184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient-reported Outcomes in Asian Patients With Chronic Hepatitis C Treated With Ledipasvir and Sofosbuvir.
    Younossi ZM; Stepanova M; Chan HLY; Lee MH; Yu ML; Dan YY; Choi MS; Henry L
    Medicine (Baltimore); 2016 Mar; 95(9):e2702. PubMed ID: 26945356
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sofosbuvir/velpatasvir improves patient-reported outcomes in HCV patients: Results from ASTRAL-1 placebo-controlled trial.
    Younossi ZM; Stepanova M; Feld J; Zeuzem S; Jacobson I; Agarwal K; Hezode C; Nader F; Henry L; Hunt S
    J Hepatol; 2016 Jul; 65(1):33-39. PubMed ID: 26956698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adherence to treatment of chronic hepatitis C: from interferon containing regimens to interferon and ribavirin free regimens.
    Younossi ZM; Stepanova M; Henry L; Nader F; Younossi Y; Hunt S
    Medicine (Baltimore); 2016 Jul; 95(28):e4151. PubMed ID: 27428205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient-Reported Outcomes of Elderly Adults with Chronic Hepatitis C Treated with Interferon- and Ribavirin-Free Regimens.
    Younossi ZM; Stepanova M; Nader F; Henry L
    J Am Geriatr Soc; 2016 Feb; 64(2):386-93. PubMed ID: 26825683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patients' preferences and health utility assessment with SF-6D and EQ-5D in patients with chronic hepatitis C treated with sofosbuvir regimens.
    Stepanova M; Nader F; Cure S; Bourhis F; Hunt S; Younossi ZM
    Aliment Pharmacol Ther; 2014 Sep; 40(6):676-85. PubMed ID: 25040192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: Results from the ION-1, -2, and -3 clinical trials.
    Younossi ZM; Stepanova M; Marcellin P; Afdhal N; Kowdley KV; Zeuzem S; Hunt SL
    Hepatology; 2015 Jun; 61(6):1798-808. PubMed ID: 25627448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improvement of health-related quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir.
    Younossi ZM; Stepanova M; Afdhal N; Kowdley KV; Zeuzem S; Henry L; Hunt SL; Marcellin P
    J Hepatol; 2015 Aug; 63(2):337-45. PubMed ID: 25795586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ribavirin-Free Regimen With Sofosbuvir and Velpatasvir Is Associated With High Efficacy and Improvement of Patient-Reported Outcomes in Patients With Genotypes 2 and 3 Chronic Hepatitis C: Results From Astral-2 and -3 Clinical Trials.
    Younossi ZM; Stepanova M; Sulkowski M; Foster GR; Reau N; Mangia A; Patel K; Bräu N; Roberts SK; Afdhal N; Nader F; Henry L; Hunt S
    Clin Infect Dis; 2016 Oct; 63(8):1042-1048. PubMed ID: 27444413
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis C Virus-Infected Patients Receiving Opioid Substitution Therapy Experience Improvement in Patient-Reported Outcomes Following Treatment With Interferon-Free Regimens.
    Stepanova M; Thompson A; Doyle J; Younossi I; de Avila L; Younossi ZM
    J Infect Dis; 2018 Mar; 217(7):1033-1043. PubMed ID: 29293991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health-related quality of life and fatigue in patients with chronic hepatitis C with therapy with direct-acting antivirals agents interferon-free.
    Fagundes RN; Ferreira LEVVC; Pace FHL
    PLoS One; 2020; 15(8):e0237005. PubMed ID: 32813740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An In-Depth Analysis of Patient-Reported Outcomes in Patients With Chronic Hepatitis C Treated With Different Anti-Viral Regimens.
    Younossi ZM; Stepanova M; Henry L; Nader F; Hunt S
    Am J Gastroenterol; 2016 Jun; 111(6):808-16. PubMed ID: 27021197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of sofosbuvir-based treatment, with and without interferon, on outcome and productivity of patients with chronic hepatitis C.
    Younossi ZM; Stepanova M; Henry L; Gane E; Jacobson IM; Lawitz E; Nelson D; Gerber L; Nader F; Hunt S
    Clin Gastroenterol Hepatol; 2014 Aug; 12(8):1349-59.e13. PubMed ID: 24316172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sofosbuvir and ledipasvir improve patient-reported outcomes in patients co-infected with hepatitis C and human immunodeficiency virus.
    Younossi ZM; Stepanova M; Sulkowski M; Naggie S; Henry L; Hunt S
    J Viral Hepat; 2016 Nov; 23(11):857-865. PubMed ID: 27291391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ledipasvir-sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens.
    Wyles D; Pockros P; Morelli G; Younes Z; Svarovskaia E; Yang JC; Pang PS; Zhu Y; McHutchison JG; Flamm S; Lawitz E
    Hepatology; 2015 Jun; 61(6):1793-7. PubMed ID: 25846014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. French Patients with Hepatitis C Treated with Direct-Acting Antiviral Combinations: The Effect on Patient-Reported Outcomes.
    Cacoub P; Bourliere M; Asselah T; De Ledinghen V; Mathurin P; Hézode C; Henry L; Stepanova M; Younossi ZM
    Value Health; 2018 Oct; 21(10):1218-1225. PubMed ID: 30314623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.